- Home
- DVAX vs JKS Comparison
DVAX vs JKS Comparison
Compare DVAX & JKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- JKS
- Stock Information
- Founded
- DVAX 1996
- JKS 2006
- Country
- DVAX United States
- JKS China
- Employees
- DVAX N/A
- JKS N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- JKS Semiconductors
- Sector
- DVAX Health Care
- JKS Technology
- Exchange
- DVAX Nasdaq
- JKS Nasdaq
- Market Cap
- DVAX 1.2B
- JKS 1.2B
- IPO Year
- DVAX 2004
- JKS 2010
- Fundamental
- Price
- DVAX $10.44
- JKS $22.55
- Analyst Decision
- DVAX Buy
- JKS Sell
- Analyst Count
- DVAX 4
- JKS 4
- Target Price
- DVAX $26.50
- JKS $28.99
- AVG Volume (30 Days)
- DVAX 1.3M
- JKS 577.7K
- Earning Date
- DVAX 11-05-2025
- JKS 11-17-2025
- Dividend Yield
- DVAX N/A
- JKS 6.96%
- EPS Growth
- DVAX N/A
- JKS N/A
- EPS
- DVAX N/A
- JKS N/A
- Revenue
- DVAX $316,268,000.00
- JKS $11,445,691,729.00
- Revenue This Year
- DVAX $23.23
- JKS N/A
- Revenue Next Year
- DVAX $16.57
- JKS $31.06
- P/E Ratio
- DVAX N/A
- JKS N/A
- Revenue Growth
- DVAX 26.66
- JKS N/A
- 52 Week Low
- DVAX $9.20
- JKS $13.42
- 52 Week High
- DVAX $14.63
- JKS $29.80
- Technical
- Relative Strength Index (RSI)
- DVAX 58.99
- JKS 45.48
- Support Level
- DVAX $10.03
- JKS $20.97
- Resistance Level
- DVAX $10.59
- JKS $23.72
- Average True Range (ATR)
- DVAX 0.22
- JKS 1.07
- MACD
- DVAX 0.06
- JKS -0.14
- Stochastic Oscillator
- DVAX 81.25
- JKS 36.22
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About JKS JinkoSolar Holding Company Limited (each representing 4)
JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), North America, Europe, Asia Pacific, and the Rest of the world.